Clinical features of complex karyotype in newly diagnosed acute myeloid leukemia

Int J Hematol. 2023 Apr;117(4):544-552. doi: 10.1007/s12185-022-03522-6. Epub 2022 Dec 26.

Abstract

Complex karyotype acute myeloid leukemia (CK-AML) has been classified as an adverse-risk subtype. Although a few reports have further classified CK-AML as typical (including monosomy of chromosomes 5, 7 and 17 or deletion of 5q, 7q and/or 17p) or atypical, the clinical features of these subtypes in Japanese patients remain unclear. We retrospectively analyzed a total of 115 patients with CK-AML, including 77 with typical CK-AML and 38 with atypical CK-AML. Median overall survival (OS) was significantly shorter in patients with typical CK-AML than atypical CK-AML (143 days vs. 369 days, P = 0.009). Among patients with typical CK-AML, those with monosomy 17 or deletion of 17p had significantly shorter OS than patients without such abnormalities (105 days vs. 165 days, P = 0.033). TP53 mutations were more predominant in patients with typical CK-AML than in patients with atypical CK-AML (69.7% vs. 32.4%, P < 0.001). Patients with typical CK-AML had a poor prognosis regardless of TP53 mutation status. Among patients with atypical CK-AML, however, prognosis was worse for those with the TP53 mutation than those without the mutation. In conclusion, prognosis is extremely poor for both typical CK-AML and atypical CK-AML with TP53 mutation.

Keywords: CK-AML; Complex karyotype; Deletion of 17p; Monosomy 17; TP53 mutation; Typical CK-AML.

MeSH terms

  • Abnormal Karyotype
  • Humans
  • Karyotype
  • Leukemia, Myeloid, Acute* / diagnosis
  • Leukemia, Myeloid, Acute* / genetics
  • Monosomy
  • Mutation
  • Prognosis
  • Retrospective Studies
  • Tumor Suppressor Protein p53 / genetics

Substances

  • Tumor Suppressor Protein p53